This is the basis for immune checkpoint blockade where antibodies such as ipilimumab (α-CTLA-4), pembrolizumab (α-PD-1) and nivolumab (α-PD-1) interfere with the engagement of the inhibitory ligand with the receptor to maximize anti-tumor immunity (Figure 2). The gene discussed is CTLA4; the disease is neoplasm.